Alzheimer's disease (AD) is the most common form of dementia among the elderly with women exhibiting a higher risk than men for the disease. Due to these gender differences, there is great interest in the role that estrogens play in cognitive impairment and the onset of the classic amyloid and tau lesions in AD. Human and rodent studies indicate a strong association between low brain aromatase, sex hormone levels, and beta amyloid deposition. Therefore, the effects of depleting both circulating and brain estrogen levels, through gonadectomy and/or treatment with the aromatase inhibitor, anastrozole, upon hippocampal ADlike pathology in male and female 3xTgAD mice were evaluated. Liquid chromatography-mass spectrometry revealed anastrozole serum levels of 10.19 ng/mL and for the first time brain levels were detected at 4.7 pg/mL. Densitometric analysis of the hippocampus revealed that anastrozole significantly increased Aβ-but not APP/Aβ-immunoreactivity in intact 3xTgAD females compared to controls (pb 0.001). Moreover, anastrozole significantly increased the number of Aβ-compared to APP/Aβ-positive hippocampal CA1 neurons in intact and gonadectomized female mice. Concurrently, anastrozole significantly reduced the APP/Aβ plaque load in 9 month old female 3xTgAD mice. These data suggest that anastrozole treatment differentially affects select amyloid species which in turn may play a role in the extraneuronal to intraneuronal deposition of this peptide.
Introduction
Alzheimer's disease (AD) is the most common form of dementia among the elderly. Although age is a major risk factor for this disease, the relatively rapid decrease in endogenous estrogen levels during menopause (Boyar et al., 1972; Gao et al., 1998) has been attributed to the higher risk for developing AD in women, compared to men (Andersen et al., 1999; Gao et al., 1998; Hy and Keller, 2000; unlisted, 1994) . Conversely, males experience a gradual depletion of testosterone that can manifest in dysfunction of androgen-responsive tissues, including the brain (Morley, 2001) , and lower serum testosterone levels correlate with increased incidence of AD in men but not women (Hogervorst et al., 2001) . The mechanism(s) underlying the role that sex hormones play in the development of AD remain unclear.
The hippocampus is selectively vulnerable in AD (Braak et al., 2006; Braak and Braak, 1991) , is responsive to estrogen (Weiland et al., 1997) , and is sensitive to both natural fluctuations in circulating (Woolley et al., 1990) as well as experimentally-manipulated estrogen depletion (Gould et al., 1990; Woolley and McEwen, 1992; Woolley and McEwen, 1993; Woolley et al., 1996) . Recent evidence suggests that hormone manipulation alters the development of the classic AD neuropathologic lesions, intraneuronal beta amyloid (Aβ) and hyperphosphorylated tau, within the hippocampus in transgenic mouse models of this disease (Carroll et al., 2007; Carroll et al., 2010; Rosario et al., 2010; Rosario et al., 2006) . Aromatase, which converts androgens to estrogens, may also contribute to amyloid deposition.
Aromatase is a member of the CYP450 superfamily and is found in the ovaries, adrenal glands, adipose tissues and brain. During menopause, the primary source of estrogen switches from ovarian, for systemic distribution, to tissue-specific synthesis for local effects (Grodin et al., 1973) , which are independent of circulating levels of sex steroids (Mukai et al., 2010) . Recent studies evaluated local brain hormone and serum levels in non-demented and demented individuals (Yue et al., 2005) , which identified region-specific changes in brain aromatase (Ishunina et al., 2005) . These data indicate a negative correlation between brain aromatase mRNA levels and plaque density in male and female AD patients (Yue et al., 2005) . While the functional consequences of brain aromatase remain unknown, many women 
